Xyloaid® Injection (Lidocaine HCl + Adrenaline)

Description

Xyloaid Injection contains Lidocaine Hydrochloride (a local anesthetic) combined with Adrenaline (Epinephrine) (a vasoconstrictor), representing a classic and widely used combination in local and regional anesthesia where Lidocaine rapidly blocks voltage-gated sodium channels in neuronal membranes, preventing the initiation and propagation of nerve impulses and producing complete reversible loss of sensation in the targeted area, while Adrenaline acts synergistically by causing local vasoconstriction through alpha-1 adrenergic receptor stimulation, thereby reducing systemic absorption of Lidocaine, prolonging the duration of anesthetic action, decreasing the risk of systemic toxicity, and minimizing bleeding at the injection site. The addition of Adrenaline to Lidocaine significantly extends the duration of local anesthesia from approximately 1–2 hours to 2–4 hours, making the combination particularly valuable in procedures requiring prolonged anesthesia, and the vasoconstrictive effect also provides a relatively bloodless operative field that improves surgical visibility and precision. It is widely indicated for infiltration anesthesia, nerve blocks, dental anesthesia, epidural anesthesia, and regional anesthesia in minor surgical procedures, wound suturing, dental extractions, and diagnostic interventions requiring local pain control in various clinical settings including surgery, dentistry, and emergency medicine. The combination is contraindicated for use in end-arterial regions such as fingers, toes, ears, nose, and penis due to the risk of ischemic necrosis from vasoconstriction, and should be used with extreme caution in patients with cardiac arrhythmias, uncontrolled hypertension, hyperthyroidism, and those on MAO inhibitors or tricyclic antidepressants, with inadvertent intravascular injection being the most serious risk requiring strict aspiration before administration.